Competitive inhibitor of monoamine neurotransmitter transporters. Inhibits dopamine (DAT), serotonin (SERT) and noradrenalin (NET) transporters with Ki values are 267, 392 and 872 nM respectively. Psychostimulant.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 339.81. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.94 mL||14.71 mL||29.43 mL|
|5 mM||0.59 mL||2.94 mL||5.89 mL|
|10 mM||0.29 mL||1.47 mL||2.94 mL|
|50 mM||0.06 mL||0.29 mL||0.59 mL|
References are publications that support the biological activity of the product.
Fleckenstein et al (2000) Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur.J.Pharmacol. 406 1 PMID: 11011026
Torres et al (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat.Rev.Neurosci. 4 13 PMID: 12511858
If you know of a relevant reference for Cocaine hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Cocaine hydrochloride, Cocaine hydrochloride supplier, inhibitors, inhibits, monoamine, transporters, noradrenalin, noradrenaline, NET, adrenergic, neurotransmitter, DAT, dopamine, serotonin, SERT, 5-HT, reuptake, 5-Hydroxytryptamine, Dopamine, Transporters, Adrenergic, 2833, Tocris Bioscience
3 Citations for Cocaine hydrochloride
Citations are publications that use Tocris products. Selected citations for Cocaine hydrochloride include:
Luu and Malenka (2008) Spike timing-dependent long-term potentiation in ventral tegmental area dopamine cells requires PKC. J Neurophysiol 100 533 PMID: 18450581
Rennekamp et al (2016) σ1 receptor ligands control a switch between passive and active threat responses. Nat Chem Biol 12 552 PMID: 27239788
Ferraro et al (2012) A novel mechanism of cocaine to enhance dopamine d2-like receptor mediated neurochemical and behavioral effects. An in vivo and in vitro study. Neuropsychopharmacology 37 1856 PMID: 22453136
Do you know of a great paper that uses Cocaine hydrochloride from Tocris? Please let us know.
Reviews for Cocaine hydrochloride
There are currently no reviews for this product. Be the first to review Cocaine hydrochloride and earn rewards!
Have you used Cocaine hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.